Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 18Prostatic Neoplasms 16Breast Neoplasms 11Recurrence 8Leukemia, Myeloid, Acute 8Neoplasm Metastasis 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Colorectal Neoplasms 6Ovarian Neoplasms 5Myelodysplastic Syndromes 5Multiple Myeloma 5Melanoma 5Leukemia 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Fatigue 4Vomiting 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms, Castration-Resistant 3Pain 3Oropharyngeal Neoplasms 3Nausea 3Mesothelioma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Liposarcoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

plerixafor 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Agammaglobulinemia × Clear all
NCT02231879 2023-04-07

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2/3 Completed
20 enrolled 10 charts

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡